Education
About Us
Working with TipRanks
Follow Us
Bone Biologics Corp. (BBLG)
NASDAQ:BBLG
Total Valuation
Bone Biologics has a market cap or net worth of $3.36M. The enterprise value is ―.
Market Cap$3.36M
Enterprise Value―
Share Statistics
Bone Biologics has 1,795,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,795,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bone Biologics’s return on equity (ROE) is -1.18 and return on invested capital (ROIC) is -121.11%.
Return on Equity (ROE)-1.18
Return on Assets (ROA)-1.06
Return on Invested Capital (ROIC)-121.11%
Return on Capital Employed (ROCE)-1.21
Revenue Per Employee0.00
Profits Per Employee-2.06M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bone Biologics is ―. Bone Biologics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.46
Price to Fair Value2.46
Price to FCF-2.07
Price to Operating Cash Flow-0.76
PEG Ratio0.02
Income Statement
In the last 12 months, Bone Biologics had revenue of 0.00 and earned -4.11M in profits. Earnings per share was -4.83.
Revenue0.00
Gross Profit0.00
Operating Income-4.22M
Pretax Income-4.11M
Net Income-4.11M
EBITDA107.16K
Earnings Per Share (EPS)-4.83
Cash Flow
In the last 12 months, operating cash flow was -3.33M and capital expenditures 0.00, giving a free cash flow of -3.33M billion.
Operating Cash Flow-3.33M
Free Cash Flow-3.33M
Free Cash Flow per Share-1.85
Dividends & Yields
Bone Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change-63.89%
50-Day Moving Average1.93
200-Day Moving Average3.22
Relative Strength Index (RSI)54.30
Average Volume (3m)155.76K
Important Dates
Bone Biologics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Bone Biologics as a current ratio of 10.22, with Debt / Equity ratio of 0.00%
Current Ratio10.22
Quick Ratio10.22
Debt to Market Cap0.00
Net Debt to EBITDA-31.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bone Biologics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bone Biologics EV to EBITDA ratio is 48.81, with an EV/FCF ratio of -1.27.
EV to Sales0.00
EV to EBITDA48.81
EV to Free Cash Flow-1.27
EV to Operating Cash Flow-1.27
Balance Sheet
Bone Biologics has $6.05M in cash and marketable securities with $0.00 in debt, giving a net cash position of $6.05M billion.
Cash & Marketable Securities$6.05M
Total Debt$0.00
Net Cash$6.05M
Net Cash Per Share$3.37
Tangible Book Value Per Share$2.30
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bone Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―